NCT06913075 - FET in Adenomyosis | Biotech Hunter

Enrollment

700

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

January 23, 2026

Conditions

Adenomyosis

Interventions

DRUG

GnRH agonist downregulation

Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval

DRUG

GnRH agonist and Letrozole

Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts

Trial Locations (1)

313001

Indira IVF Pvt Hospital, Udaipur

All Listed Sponsors

lead

Indira IVF Hospital Pvt Ltd

OTHER